Skip to Content

11 17 WPI (Mirtazapine 15 mg)

Pill imprint 11 17 WPI has been identified as Mirtazapine 15 mg.

Mirtazapine is used in the treatment of major depressive disorder; insomnia; anxiety; depression; post traumatic stress disorder (and more), and belongs to the drug class tetracyclic antidepressants. Risk cannot be ruled out during pregnancy. Mirtazapine 15 mg is classified as a Schedule N controlled substance under the Controlled Substance Act (CSA).

Mirtazapine 15 mg 11 17 WPI Front
Mirtazapine 15 mg 11 17 WPI Back
Mirtazapine 15 mg 11 17 WPI
11 17
15 mg
10.00 mm
Elliptical / Oval
Prescription only
Drug Class:
Tetracyclic antidepressants
Pregnancy Category:
C - Risk cannot be ruled out
CSA Schedule:
N - Not a controlled drug
Watson Pharmaceuticals
National Drug Code (NDC):
Inactive Ingredients:
lactose anhydrous
silicon dioxide
magnesium stearate
microcrystalline cellulose
hypromellose 2910 (3 mPa.s)
hypromellose 2910 (6 mPa.s)
polyethylene glycol 400
polysorbate 80
titanium dioxide
Other Manufacturers / Repackagers:
NDC CodeManufacturer / Repackager
63874-1098 Altura Pharmaceuticals Inc (repackager)
58016-0894 Southwood Pharmaceuticals Inc (repackager)
16590-0153 Stat RX USA LLC (repackager)
68258-7004 Dispensing Solutions Inc. (repackager)

Note: Inactive ingredients may vary.

View Details Print Page Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2015, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.